Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant versus standard endocrine therapy as extended adjuvant treatment for ER-positive/HER2-negative early breast cancer
NL-OMON60651Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival. Started Jul 2023; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60651.